NCT02259881View on ClinicalTrials.gov

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

May 31, 2003

Conditions
Healthy
Interventions
DRUG

Low dose of BIBT 986 CL, per i.v. infusion

DRUG

Medium dose of BIBT 986 CL, per i.v. infusion

DRUG

High dose of BIBT 986 CL, per i.v. infusion

DRUG

Placebo

DRUG

Lipopolysaccharide (LPS), single i.v. bolus

Endotoxin derived from E. coli bacteria, used for activation of coagulation

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02259881 - Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter